查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2003000

病毒载体市场：按载体类型、治疗领域、生产阶段、应用和最终用户划分－2026-2032年全球市场预测

Viral Vectors Market by Vector Type, Therapeutic Area, Production Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，病毒载体市场价值将达到 21.5 亿美元，到 2026 年将成长到 24.6 亿美元，到 2032 年将达到 56 亿美元，复合年增长率为 14.63%。

主要市场统计数据
基准年 2025 21.5亿美元
预计年份：2026年 24.6亿美元
预测年份 2032 56亿美元
复合年增长率 (%) 14.63%

为处于技术、监管和商业交汇点的领导者提供病毒载体生态系统的简明概述。

病毒载体目前处于前沿生物学和复杂製造技术的交汇点。本入门指南全面说明了核心科学原理、关键製造环节以及将研究成果转化为临床应用的转化路径。指南重点在于载体生物学（衣壳选择、嗜性和有效载荷设计）如何与上游工程细胞培养、转染方法和下游纯化等製程因素相互作用，从而决定专案的整体可行性和进度安排。

技术创新、不断变化的法规和供应链的韧性正在推动病毒载体的开发和交付发生根本性变革。

多种因素共同作用，重塑了病毒载体的格局。载体工程技术的进步——包括改进的衣壳设计、新型血清型和优化的基因组建构——正在拓展组织标靶化和安全性，从而拓宽治疗应用范围。同时，分析技术的进步，例如次世代定序和高解析度杂质分析，正在对产品进行严格的表征，并为不同製程变体之间的比较提供更可靠的策略。

评估近期关税政策对 2025 年病毒载体生产投入品供应链、成本和策略采购的累积影响。

近期关税措施和贸易政策的变化为病毒载体生产所需的原材料、设备和专用耗材的采购计划带来了新的变数。这些累积的影响不仅体现在直接组件成本上，还体现在采购前置作业时间、供应商谈判和库存策略等。依赖进口一次性系统、专用层析法树脂或独家设备的工厂可能会面临更长的合格週期和更高的接收成本。这迫使专案团队重新评估供应商冗余和在地采购方案。

基于市场区隔的关键洞察揭示了技术、临床和商业性差异化如何为整个病毒载体市场创造策略机会。

細項分析揭示了载体生物学、应用领域、治疗标靶、最终用户、生产阶段和规模等方面的价值和风险集中。依载体类型分类，腺结合病毒(AAV)、腺病毒、慢病毒和逆转录病毒各自展现出不同的权衡取舍。腺结合病毒通常在安全性和组织亲和性具有显着优势，而 AAV2、AAV8 和 AAV9 是常用的血清型，它们在生物分布和既有免疫学因素方面存在差异。腺病毒在瞬时表达中具有高载药量和转导效率。慢病毒和逆转录病毒是体外细胞治疗等持续性和整合性疗法的基础。这些差异要求针对每种载体制定个人化的最佳化生产和分析策略，以使分子特性与治疗目标相符。

影响各司法管辖区准入、製造策略和伙伴关係模式的区域趋势：北美和南美、欧洲、中东和非洲以及亚太地区。

区域因素对病毒载体的开发和部署的策略选择有显着影响。在美洲，成熟的生物技术丛集和先进的製造网络支持快速转化途径和对接专业合约研发生产机构（CDMO），但专案团队也必须应对影响商业化策略的当地监管要求和报销环境。在欧洲、中东和非洲（EMEA）地区，监管协调的努力和各国医疗保健体系的多样性为跨国合作创造了机会，同时也使临床试验设计变得更加复杂。在此，与成熟的本地製造商和学术机构建立合作关係可以简化患者获取途径，同时遵守区域合规框架。在亚太地区，GMP生产能力的快速扩张、不断壮大的本地科研人才库以及对国内生物製造的政策奖励正在加速产能增长，但申办方必须仔细评估区域供应的可靠性以及在地采购要求和知识产权问题的影响。

竞争考察与合作的企业洞察，重点在于病毒载体生态系统中的能力丛集、典型伙伴关係与策略重点。

根据核心能力，病毒载体领域的主要企业可分为以下几类：专注于平台工程和衣壳发现的公司、专长于可扩展GMP生产的供应商以及提供端到端开发支援的整合商。平台创新者优先考虑先进的分子工程、前沿分析以及与血清型设计和免疫逃脱策略相关的智慧财产权组合，并通常支持跨多个治疗领域的临床计画。生产专家专注于製程稳健性、高产量上游工程平台和下游纯化技术，以解决长期存在的瓶颈问题。整合商和CDMO则连接这些能力，提供模组化服务，使申办者能够以可预测的进度和监管支援加速临床供应。

行业领导者现在应该实施的实用建议，以确保病毒载体专案的连续性、监管合规性和商业化准备。

优先制定整合的早期研发计划，使衣壳选择、有效载荷设计和生产策略与监管要求保持一致。让监管和品质专家参与早期决策，可以降低后期出现意外问题的风险，并在需要进行製程变更时简化可比性。同时，儘早投资于分析能力建设，建立可靠的效力和杂质检测方法，以支持新药临床试验申请（IND）和未来的生产转移。

病毒载体领域内所有研究途径和调查方法，旨在产生稳健、可重复且具有决策意义的见解。

本研究整合了对行业专家的访谈、对监管指南的定性分析以及技术文献中的证据，对病毒载体开发中的运营和战略影响进行了多角度的检验。一级资讯来源包括製程开发、分析科学、品管和商业领域的专家，他们提供了关于製程瓶颈、技术应用和伙伴关係趋势的全面见解。二级资讯来源，包括同行评审的研究、监管指南文件和公开讯息，用于阐明技术说明的依据并检验观察到的行业趋势。

摘要重申了策略重点，并重点介绍了成功开发病毒载体的最关键操作因素。

最根本的教训是，仅靠科学进步并不能保证专案成功。营运执行、监管前瞻性和供应链设计同样至关重要。病毒载体专案的成功取决于载体选择和有效载荷设计与可扩展生产流程的匹配，从早期阶段融入严谨的分析，以及建立能够提供技术能力和供应连续性的伙伴关係。采用模组化生产方法、投资精细分析开发并积极管理供应商风险的机构，将更有能力把有前景的生物科学成果转化为可靠的临床和商业供应。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以载体类型分類的病毒载体市场

  • 腺结合病毒
    • AAV2
    • AAV8
    • AAV9
  • 腺病毒
  • 慢病毒
  • 逆转录病毒

第九章：病毒载体市场：依治疗领域划分

  • 心血管疾病
    • 冠状动脉
    • 週边血管
  • 感染疾病
    • 细菌
    • 病毒
  • 神经系统疾病
    • 神经退化性疾病
    • 神经发育障碍
  • 肿瘤学
    • 血液疾病
    • 固体癌
  • 罕见疾病

第十章：病毒载体市场依生产阶段划分

  • 下游
    • 过滤
    • 配方
    • 纯化
      • 层析法
      • 超速离心
  • 上游
    • 细胞增殖
    • 收成
    • 转染

第十一章：病毒载体市场：依应用划分

  • 细胞疗法
    • CAR-T
    • 树突状细胞
    • TCR T
  • 基因治疗
    • Ex Vivo
    • In vivo
  • 调查
    • 基础研究
    • 临床前研究
  • 疫苗
    • 预防
    • 治疗

第十二章：病毒载体市场：依最终用户划分

  • 生物製药公司
  • 医院和诊所
  • 研究机构

第十三章：病毒载体市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：病毒载体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：病毒载体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国病毒载体市场

第十七章：中国病毒载体市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ABL Inc.
  • Batavia Biosciences BV by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure NV
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-957C47F9405B

The Viral Vectors Market was valued at USD 2.15 billion in 2025 and is projected to grow to USD 2.46 billion in 2026, with a CAGR of 14.63%, reaching USD 5.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.15 billion
Estimated Year [2026] USD 2.46 billion
Forecast Year [2032] USD 5.60 billion
CAGR (%) 14.63%

A concise orientation to the viral vectors ecosystem that prepares leaders for technical, regulatory, and commercial intersections

Viral vectors now sit at the intersection of cutting-edge biology and complex manufacturing. This introduction synthesizes the core scientific modalities, the critical manufacturing inflection points, and the translational pathways that convert research signals into clinical programs. It focuses on how vector biology-capsid selection, tropism, and payload design-interacts with process considerations such as upstream cell culture, transfection methods, and downstream purification to determine overall program feasibility and timelines.

Across the development lifecycle, regulatory expectations and analytical requirements increasingly shape design choices. As a result, early decisions about vector type, production platform, and quality attributes cascade into downstream risk profiles for clinical comparability and commercial supply. Accordingly, this section frames the primary operational and strategic tradeoffs decision-makers must weigh when selecting partners, investing in in-house capabilities, or designing clinical development plans. The aim is to equip executives, program leads, and manufacturing planners with a cohesive mental model that clarifies where scientific opportunity aligns with manufacturing practicality and regulatory acceptability.

How technological innovations, regulatory evolution, and supply chain resilience are driving foundational shifts in viral vector development and delivery

The landscape for viral vectors is being reshaped by several converging forces. Advances in vector engineering-improved capsid design, novel serotypes, and optimized genome constructs-are expanding tissue targeting and safety profiles, which in turn broaden therapeutic applicability. Parallel progress in analytical methods, including next-generation sequencing and high-resolution impurity profiling, has tightened product characterization and enabled more confident comparability strategies between process variants.

On the manufacturing front, modular bioprocessing and single-use technologies are driving faster campaign turnarounds and lower capital exposure for early clinical work. At the same time, the maturation of scalable chromatography chemistries and alternative purification approaches is enabling manufacturers to tackle persistent yield and purity challenges. Regulatory bodies are also evolving their expectations; regulators are emphasizing robust control strategies, detailed characterization of impurities, and clearer bridging requirements for manufacturing changes, prompting sponsors to integrate regulatory thinking earlier into development plans.

Finally, the global supply chain and geopolitical context are encouraging stakeholders to diversify sourcing, localize critical production steps, and cultivate strategic supplier relationships. Together, these technological, regulatory, and operational shifts are redefining viable commercial models and the timelines for safely moving therapies from lab to clinic.

Assessment of cumulative effects from recent tariff policies on supply chains, costs, and strategic sourcing for viral vector production inputs in 2025

Recent tariff measures and trade policy shifts have introduced new variables into the sourcing calculus for raw materials, equipment, and specialized consumables used in viral vector manufacturing. The cumulative impact is felt not only in direct component costs but also in procurement lead times, supplier negotiations, and inventory strategies. Facilities that rely on imported single-use systems, specialized chromatography resins, or proprietary equipment may experience extended qualification timelines and higher landed costs, prompting program teams to reassess supplier redundancy and localized sourcing options.

Beyond direct procurement, tariffs can influence capital planning decisions. Organizations evaluating new cleanroom builds, fill-finish capacity, or onshore contract manufacturing partnerships must now weigh altered equipment import economics and vendor availability. This has sharpened interest in modular and mobile manufacturing approaches that reduce heavy equipment dependence and allow incremental capacity expansion. Furthermore, tariff-driven variability has highlighted the importance of robust supplier performance metrics, dual sourcing for critical reagents, and strategic stockpiling where shelf life and stability allow.

Ultimately, while tariffs add friction and cost pressure, they also accelerate strategic shifts toward supply chain resilience, critical supplier partnerships, and regional manufacturing footprints that balance risk with operational flexibility.

Key segmentation-driven insights that clarify where technical, clinical, and commercial differentiation creates strategic opportunity across the viral vectors market

Segmentation illuminates where value and risk concentrate across vector biology, application areas, therapeutic targets, end users, production stages, and scale. When categorized by vector type, Adeno Associated Virus, Adenovirus, Lentivirus, and Retrovirus each present distinct tradeoffs: Adeno Associated Virus generally offers strong safety and tissue tropism advantages, with AAV2, AAV8, and AAV9 representing commonly referenced serotypes that differ in biodistribution and preexisting immunity considerations; Adenovirus provides high payload capacity and transduction efficiency for transient expression; Lentivirus and Retrovirus are foundational for durable, integrating approaches such as ex vivo cell therapies. These differences demand tailored manufacturing and analytical strategies that match molecular attributes to therapeutic intent.

Application segmentation underscores divergent development and manufacturing pathways. Cell Therapy, Gene Therapy, Research, and Vaccine applications have unique process and regulatory footprints. Within Cell Therapy, CAR T, Dendritic, and TCR T modalities pose specific vector dosing, potency assay, and safety testing needs. Gene Therapy divides into Ex Vivo and In Vivo approaches, each with differing vector purity and biodistribution requirements. Research applications span Basic Research and Preclinical Research, driving demand for flexible small-scale production and rapid turnaround, while Vaccine programs-both Prophylactic and Therapeutic-prioritize scalable, cost-efficient manufacturing and batch traceability.

Therapeutic area segmentation-Cardiovascular Disorders, Infectious Disease, Neurological Disorders, Oncology, and Rare Diseases-further refines prioritization. Cardiovascular programs split into coronary and peripheral vascular focuses with distinct delivery challenges; Infectious Disease divides into bacterial and viral targets that impact antigen design and immunogenicity management; Neurological Disorders separate into neurodegenerative and neurodevelopmental conditions that influence administration routes and safety monitoring; Oncology programs bifurcate into hematological and solid tumor strategies with differing cell targeting and tumor microenvironment considerations; Rare Diseases, often monogenic, demand highly individualized product strategies and flexible manufacturing capable of low-volume, high-complexity production.

End users-Biopharma Companies, Hospitals And Clinics, and Research Institutes-drive different demand profiles and service expectations. Biopharma companies often require integrated development and commercial scale solutions, hospitals and clinics emphasize parenteral formulation, cold chain logistics, and point-of-care readiness, while research institutes prioritize rapid access and methodological flexibility. Production stage segmentation between Downstream and Upstream highlights where investment in filtration, formulation, purification and cell expansion, harvesting, and transfection deliver the greatest operational leverage. Downstream purification, including chromatography and ultracentrifugation, remains a persistent bottleneck for purity and yield, whereas upstream improvements in cell expansion and transfection efficiency directly enhance vector productivity. Finally, production scale segmentation-Clinical and Commercial-reflects different operational cadences: clinical work requires nimble phase-specific manufacturing across Phase I, Phase II, and Phase III, while commercial full-scale operations emphasize reproducibility, cost of goods optimization, and long-term supply agreements.

Taken together, these segmentation layers provide a multidimensional map for prioritizing technology investments, partnership models, and manufacturing footprints based on therapeutic modality, target population, and commercialization pathway.

Regional dynamics shaping access, manufacturing strategy, and partnership models across the Americas, EMEA, and Asia-Pacific jurisdictions

Regional factors strongly influence strategic choices for viral vector development and deployment. In the Americas, established biotech clusters and advanced manufacturing networks support rapid translational pathways and access to specialized CDMOs, but program teams must also navigate regional regulatory expectations and reimbursement landscapes that affect commercialization strategies. In Europe, Middle East & Africa, regulatory harmonization efforts and diverse national health systems create both opportunities for cross-border collaboration and complexity for clinical trial design; here, partnerships with established local manufacturers and academic centers can streamline patient access while aligning to regional compliance frameworks. In the Asia-Pacific region, rapid expansion of GMP capacity, growing local scientific talent pools, and policy incentives for domestic biomanufacturing are accelerating capacity growth, though sponsors must carefully assess regional supply reliability and the implications of local content and intellectual property considerations.

Across these regions, clinical trial recruitment dynamics, prevalence of target indications, and payer evaluation criteria differ significantly, which informs where to site pivotal studies and how to structure market access strategies. Manufacturing location decisions are similarly sensitive to regional cost structures, talent availability, and proximity to patient populations. Given these variances, companies are increasingly adopting hybrid models that pair regional development hubs with distributed manufacturing to balance cost, regulatory alignment, and time to patient. Ultimately, regional strategy must be tightly integrated with product profiling, clinical design, and commercial access planning to ensure successful translation from development to widespread use.

Competitive and collaborative company insights that highlight capability clusters, partnership archetypes, and strategic priorities in the viral vectors ecosystem

Leading organizations in the viral vector space can be grouped by core capabilities: those focused on platform engineering and capsid discovery, providers specializing in scalable GMP manufacturing, and integrators offering end-to-end development support. Platform innovators prioritize deep molecular engineering, advanced analytics, and IP portfolios around serotype design and immune evasion strategies, typically supporting multiple clinical programs across therapeutic areas. Manufacturing specialists emphasize process robustness, high-yield upstream platforms, and downstream purification technologies that address persistent bottlenecks. Integrators and CDMOs bridge these capabilities, offering modular services that allow sponsors to accelerate clinical supply with predictable timelines and regulatory support.

Strategic partnerships are increasingly common, with technology licensors working alongside CDMOs and academic translational groups to de-risk early programs and to scale successful candidates. Companies are also competing on service breadth, geographic footprint, and the ability to manage complex comparability exercises. Investment in analytical development, digital batch records, and quality automation is a differentiator for organizations aiming to move from clinical to commercial supply. For executives assessing partners, alignment on quality culture, data transparency, and contingency planning for supply continuity are the most important indicators of long-term reliability.

Actionable recommendations that industry leaders should deploy now to secure development continuity, regulatory alignment, and commercial readiness for viral vector programs

Prioritize integrated early-stage planning that ties capsid selection, payload design, and manufacturing strategy to regulatory expectations. Embedding regulatory and quality experts into early program decisions reduces the risk of late-stage surprises and simplifies comparability when process changes become necessary. Concurrently, invest in analytical depth early to establish robust potency and impurity assays that will support both IND filings and future manufacturing transfers.

Strengthen supply chain resilience through dual sourcing of critical consumables and by qualifying regional suppliers to shorten lead times. Where feasible, adopt modular or single-use manufacturing elements to accelerate clinical supply without heavy capital commitments. For longer-term strategies, assess hybrid manufacturing footprints that combine regional clinical supply hubs with centralized commercial capacity to optimize cost and ensure patient access.

Negotiate partnership agreements that include clear quality metrics, data access provisions, and contingency clauses for supply disruptions. Finally, align commercial planning with clinical development by engaging market access and medical affairs early to define evidence generation needs and patient access pathways, thereby smoothing the transition from regulatory approval to real-world use.

Research approach and methodologies employed to produce robust, reproducible, and decision-grade insights across the viral vectors domain

This research synthesizes evidence from primary interviews with industry experts, qualitative analyses of regulatory guidance, and technical literature to triangulate the operational and strategic implications for viral vector development. Primary sources include subject matter experts across process development, analytical science, quality, and commercial functions, providing a composite view of process bottlenecks, technology adoption, and partnership behaviors. Secondary inputs draw on peer-reviewed studies, regulatory guidance documents, and public disclosures to ground technical descriptions and to validate observed industry trends.

Analytical rigor is achieved through cross-validation of qualitative insights with technical feasibility checks, for example correlating described upstream yields with downstream purification constraints to assess realistic process throughput. The methodology prioritizes transparency about evidence provenance, explicitly flagging where conclusions derive from consensus expert judgment versus established public documentation. Limitations and sensitivity considerations are noted throughout to support responsible interpretation and to guide areas for additional primary data collection where required.

Concluding synthesis that reaffirms strategic priorities and highlights the most consequential operational levers for viral vector success

The fundamental takeaway is that scientific advances alone will not guarantee program success; operational execution, regulatory foresight, and supply chain design are equally determinative. Success in viral vector programs depends on aligning vector selection and payload design with scalable manufacturing processes, embedding analytical rigor early, and structuring partnerships that offer both technical capability and supply continuity. Organizations that adopt modular manufacturing approaches, invest in deep analytical development, and proactively manage supplier risk will be better positioned to translate promising biological science into reliable clinical and commercial supply.

As the ecosystem matures, leaders should treat capability building as a strategic priority rather than an operational afterthought. This means committing resources to quality systems, process characterization, and strategic supplier relationships while maintaining flexibility to adapt to evolving regulatory expectations and geopolitical trade dynamics. In short, the path to durable value lies in marrying scientific innovation with disciplined operational practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vectors Market, by Vector Type

  • 8.1. Adeno Associated Virus
    • 8.1.1. AAV2
    • 8.1.2. AAV8
    • 8.1.3. AAV9
  • 8.2. Adenovirus
  • 8.3. Lentivirus
  • 8.4. Retrovirus

9. Viral Vectors Market, by Therapeutic Area

  • 9.1. Cardiovascular Disorders
    • 9.1.1. Coronary
    • 9.1.2. Peripheral Vascular
  • 9.2. Infectious Disease
    • 9.2.1. Bacterial
    • 9.2.2. Viral
  • 9.3. Neurological Disorders
    • 9.3.1. Neurodegenerative
    • 9.3.2. Neurodevelopmental
  • 9.4. Oncology
    • 9.4.1. Hematological
    • 9.4.2. Solid Tumor
  • 9.5. Rare Diseases

10. Viral Vectors Market, by Production Stage

  • 10.1. Downstream
    • 10.1.1. Filtration
    • 10.1.2. Formulation
    • 10.1.3. Purification
      • 10.1.3.1. Chromatography
      • 10.1.3.2. Ultracentrifugation
  • 10.2. Upstream
    • 10.2.1. Cell Expansion
    • 10.2.2. Harvesting
    • 10.2.3. Transfection

11. Viral Vectors Market, by Application

  • 11.1. Cell Therapy
    • 11.1.1. Car T
    • 11.1.2. Dendritic
    • 11.1.3. TCR T
  • 11.2. Gene Therapy
    • 11.2.1. Ex Vivo
    • 11.2.2. In Vivo
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Preclinical Research
  • 11.4. Vaccine
    • 11.4.1. Prophylactic
    • 11.4.2. Therapeutic

12. Viral Vectors Market, by End User

  • 12.1. Biopharma Companies
  • 12.2. Hospitals And Clinics
  • 12.3. Research Institutes

13. Viral Vectors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Viral Vectors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Viral Vectors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Viral Vectors Market

17. China Viral Vectors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ABL Inc.
  • 18.6. Batavia Biosciences B.V. by CJ Cheiljedang
  • 18.7. Biovian Oy
  • 18.8. Charles River Laboratories International, Inc.
  • 18.9. Creative Biogene
  • 18.10. Danaher Corporation
  • 18.11. FinVector Oy
  • 18.12. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 18.13. GE HealthCare Technologies, Inc.
  • 18.14. Genezen Laboratories, Inc.
  • 18.15. Kaneka Eurogentec S.A.
  • 18.16. Lonza Group Ltd.
  • 18.17. Merck KGaA
  • 18.18. Miltenyi Biotec GmbH
  • 18.19. Novartis AG
  • 18.20. Oxford Biomedica PLC
  • 18.21. Sanofi SA
  • 18.22. Sirion-Biotech GmbH
  • 18.23. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 18.24. Takara Bio Inc.
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. uniQure N.V.
  • 18.27. VGXI, Inc. by GeneOne Life Science
  • 18.28. Waisman Biomanufacturing
  • 18.29. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. GCC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. GCC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. GCC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 324. GCC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 325. GCC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 326. GCC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 327. GCC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 328. GCC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. GCC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 330. GCC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 331. GCC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 332. GCC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 333. GCC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. GCC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 335. GCC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 336. GCC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 337. GCC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 338. GCC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY